Myriad Genetics, Inc. (MYGN)
| Market Cap | 2.17B |
| Revenue (ttm) | 566.10M |
| Net Income (ttm) | -148.00M |
| Shares Out | 76.00M |
| EPS (ttm) | -0.41 |
| PE Ratio | n/a |
| Forward PE | 555.56 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $28.25 |
| Previous Close | $26.86 |
| Change ($) | 1.39 |
| Change (%) | 5.17% |
| Day's Open | 27.15 |
| Day's Range | 26.99 - 28.82 |
| Day's Volume | 398,531 |
| 52-Week Range | 10.54 - 33.97 |
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q1 sales despite pandemic-led business challenges.
Myriad (MYGN) delivered earnings and revenue surprises of 40.00% and 11.54%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
SALT LAKE CITY, May 03, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it has entered into a definitive agreement to se...
Company continues to focus on expanding its reach and organic growth, expense control, and laying foundation for advancing leadership position in genetic testing and precision medicine Company continues...
New poll shows 83% of people with depression agree life would be easier if others could understand their depression New poll shows 83% of people with depression agree life would be easier if others coul...
SALT LAKE CITY, April 27, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it will release its financial results for the ...
SALT LAKE CITY, April 27, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it has signed a definitive agreement to sell t...
Let's take a look at the three women healthcare MedTech stocks performing well lately.
Myriad Genetics' (MYGN) myChoice test's additional reimbursement will now make it available for use in first-line treatment of advanced ovarian cancer patients.
SALT LAKE CITY, March 29, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Eric Santa as its new Chief Growth Officer. I...
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
Comprehensive Test Helps Identify Women with Advanced Ovarian Cancer Who May Benefit from First-Line Lynparza® Maintenance Treatment Comprehensive Test Helps Identify Women with Advanced Ovarian Cancer ...
NEW YORK--(BUSINESS WIRE)-- #FederalSecuritiesLaws--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that the Shareholder Class Action Against Myriad Genetics,...
Myriad Genetics (MYGN) to provide a comprehensive offering utilizing germline genetic testing and somatic tumor profiling via latest collaboration with Intermountain Precision Genomics.
Strategic collaboration combines germline genetic testing, next-generation tumor sequencing and world-class testing capabilities to elevate global precision oncology care Strategic collaboration combine...
Myriad Genetics' (MYGN) sales in majority of the operating segments improved in the quarter despite pandemic-led business challenges.
Myriad (MYGN) delivered earnings and revenue surprises of 0.00% and 4.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Myriad Genetics (NASDAQ:MYGN) were unchanged in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 152.17% over the past year to ($0.12)...
New talent and promotions span core businesses, transformation, IT, revenue cycle management, business development, marketing, legal New talent and promotions span core businesses, transformation, IT, r...
SALT LAKE CITY, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it will hold its quarterly earnings conference ...
Myriad Genetics' (MYGN) new study combines a Prolaris molecular risk score approach with a clinical model for predicting a patient's benefit from androgen deprivation therapy.
Results from second study cite Prolaris® as most clinically significant prognostic parameter of outcomes at time of diagnosis, identifying men who need aggressive hormonal treatment and those who can sa...
SALT LAKE CITY, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it will participate at multiple upcoming ...
Myriad Genetics' (MYGN) GeneSight Psychotropic test is better for predicting patient outcomes and medication blood levels than single-gene testing, per new study.
New Analysis Published in Psychiatry Research
SALT LAKE CITY, Feb. 02, 2021 (GLOBE NEWSWIRE) -- To help more patients with rheumatoid arthritis (RA), Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today la...
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Patients with Prostate or Pancreatic Cancer to Benefit from Treatment with Lynparza
NEW YORK, Jan. 18, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty cl...
Myriad Genetics (MYGN) partners with Illumina to expand the access as well as extend the reach of myChoice CDx through its services offering in the international market.
Note: Paul Diaz, President & CEO of Myriad Genetics will speak today at the 39th Annual JP Morgan Healthcare Conference at 2:50 p.m. EST accessible via a live audio webcast at the following direct link ...
SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decis...
These are the stocks posting the largest moves after hours on Tuesday.
Focus on Women's Health, Oncology, Mental Health to Improve Execution and Accelerate Growth Focus on Women's Health, Oncology, Mental Health to Improve Execution and Accelerate Growth
SALT LAKE CITY, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in precision medicine and molecular diagnostics, will discuss the comp...
SALT LAKE CITY, Dec. 11, 2020 (GLOBE NEWSWIRE) -- In a spotlight poster discussion at the 2020 San Antonio Breast Cancer Symposium (SABCS), Myriad Genetics (NASDAQ: MYGN), a global leader in molecular d...
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
Myriad Genetics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating The post IBD Rating Upgrades: Myriad Genetics Flashes Improved Technical Strength appeared first on...
FRESNO, Calif., Nov. 30, 2020 /PRNewswire/ -- Integrated Prescription Management (IPM), a leading pharmacy benefits management (PBM) company, has signed a contract with Myriad Genetics, Inc. (NASDAQ: MY...
New nationwide poll shows 1 in 3 respondents age 65+ think they can just “snap out of it” New nationwide poll shows 1 in 3 respondents age 65+ think they can just “snap out of it”
SALT LAKE CITY, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today the expansion of Myriad myChoice®...
SALT LAKE CITY, Nov. 11, 2020 (GLOBE NEWSWIRE) -- At the annual meeting of the American College of Rheumatology (ACR), Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precisi...
Myriad Genetics' (MYGN) sales in majority of the operating segments plummeted in the quarter owing to the pandemic-led business challenges.
Myriad Genetics' (MYGN) CEO Paul Diaz on Q1 2021 Results - Earnings Call Transcript
Myriad (MYGN) delivered earnings and revenue surprises of 54.55% and 7.86%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
SALT LAKE CITY, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its quarterly earnings confe...
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
About MYGN
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with... [Read more...]
| Industry Diagnostics & Research | IPO Date Oct 5, 1995 |
| CEO R. Bryan Riggsbee | Employees 2,700 |
| Stock Exchange NASDAQ | Ticker Symbol MYGN |
Analyst Forecasts
According to 9 analysts, the average rating for MYGN stock is "Hold." The 12-month stock price forecast is 26.86, which is a decrease of -4.92% from the latest price.